The researchers will use Agilent's Fourier-transform infrared spectroscopy technology to monitor infants and determine those at highest risk of developing atopic eczema.
IVD manufacturers are hoping questions related to the UK's pending exit from the EU, as well as the new European IVD Regulation, will soon be resolved.
